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Dear Sirs,  
The article “Novel use of the ovarian follicular pool to postpone menopause and delay 
osteoporosis” by Andersen CY & Kristensen SG, Reprod Biomed Online 2015 May 14, 
addresses a very innovative topic. However there is one essential question which needs to 
be addressed: Is the physiological, endogenous hormone production induced by 
transplanted ovarian tissue, “Tissue menopause hormone therapy, THT”, more 
advantageous for women`s health than a conventional “Menopause hormone therapy, 
MHT”? 
Late menopause defined as last spontaneous menstruation beyond age 55 is associated with 
an increased risk of breast cancer but lower risk for cardiovascular diseases and osteoporotic 
fractures. Combined estrogen/progestogen MHT also imposes an increased risk of breast 
cancer and reduces the risk for osteoporotic fractures. However, combined MHT has a more 
or less neutral effect on the risk for myocardial infarction whereas estrogen MHT reduces 
the risk when initiated during early postmenopause. Therefore THT might indeed be a better 
option in women with an intact uterus that require combined MHT for endometrial 
protection.  
But what about hysterectomized women that only need estrogens alone? Estrogens alone 
are associated not only with a lower risk of coronary heart disease but also with lower risk of 
breast cancer. Therefore, under this condition, MHT seems to be better. 
Therefore, keeping in mind that neither a study has yet analysed the endocrine profile of 
THT and its impact on women`s health nor a comparison of THT and MHT has been 
performed, THT might be more beneficial than a combined estrogen/progestogen HRT, but 
for hysterectomized women not needing a progestogen, an estrogen only therapy seems to 
be better. For that reason we should not yet promote THT as a solution for all women and 
THTs  should only be performed as part of clinical studies. 
 
 
